These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Fogarasi A; De Waele L; Bartalini G; Jozwiak S; Laforgia N; Verhelst H; Petrak B; Pedespan JM; Witt O; Castellana R; Crippa S; Gislimberti G; Gyorsok Z BMC Neurol; 2016 Aug; 16():126. PubMed ID: 27502586 [TBL] [Abstract][Full Text] [Related]
10. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018 [TBL] [Abstract][Full Text] [Related]
11. Unique findings of subependymal giant cell astrocytoma within cortical tubers in patients with tuberous sclerosis complex: a histopathological evaluation. Katz JS; Frankel H; Ma T; Zagzag D; Liechty B; Zeev BB; Tzadok M; Devinsky O; Weiner HL; Roth J Childs Nerv Syst; 2017 Apr; 33(4):601-607. PubMed ID: 28074282 [TBL] [Abstract][Full Text] [Related]
12. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA). Weidman DR; Pole JD; Bouffet E; Taylor MD; Bartels U Pediatr Blood Cancer; 2015 Oct; 62(10):1754-60. PubMed ID: 25929843 [TBL] [Abstract][Full Text] [Related]
13. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. MacKeigan JP; Krueger DA Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591 [TBL] [Abstract][Full Text] [Related]
15. The Characterization of a Subependymal Giant Astrocytoma-Like Cell Line from Murine Astrocyte with mTORC1 Hyperactivation. Tang X; Angst G; Haas M; Yang F; Wang C Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923449 [TBL] [Abstract][Full Text] [Related]
16. Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile. Giannikou K; Zhu Z; Kim J; Winden KD; Tyburczy ME; Marron D; Parker JS; Hebert Z; Bongaarts A; Taing L; Long HW; Pisano WV; Alexandrescu S; Godlewski B; Nellist M; Kotulska K; Jozwiak S; Roszkowski M; Mandera M; Thiele EA; Lidov H; Getz G; Devinsky O; Lawrence MS; Ligon KL; Ellison DW; Sahin M; Aronica E; Meredith DM; Kwiatkowski DJ Mod Pathol; 2021 Feb; 34(2):264-279. PubMed ID: 33051600 [TBL] [Abstract][Full Text] [Related]
17. Mammalian Target of Rapamycin Inhibitor Induced Complete Remission of a Recurrent Subependymal Giant Cell Astrocytoma in a Patient Without Features of Tuberous Sclerosis Complex. Appalla D; Depalma A; Calderwood S Pediatr Blood Cancer; 2016 Jul; 63(7):1276-8. PubMed ID: 26929034 [TBL] [Abstract][Full Text] [Related]
18. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits. Feliciano DM; Lin TV; Hartman NW; Bartley CM; Kubera C; Hsieh L; Lafourcade C; O'Keefe RA; Bordey A Int J Dev Neurosci; 2013 Nov; 31(7):667-78. PubMed ID: 23485365 [TBL] [Abstract][Full Text] [Related]
19. mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia. Nguyen LH; Mahadeo T; Bordey A J Neurosci; 2019 Apr; 39(14):2762-2773. PubMed ID: 30700531 [TBL] [Abstract][Full Text] [Related]
20. Enhanced epidermal growth factor, hepatocyte growth factor, and vascular endothelial growth factor expression in tuberous sclerosis complex. Parker WE; Orlova KA; Heuer GG; Baybis M; Aronica E; Frost M; Wong M; Crino PB Am J Pathol; 2011 Jan; 178(1):296-305. PubMed ID: 21224066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]